| 000 | 01630 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515055716.0 | ||
| 264 | 0 | _c20070521 | |
| 008 | 200705s 0 0 eng d | ||
| 022 | _a0269-9370 | ||
| 024 | 7 |
_a10.1097/QAD.0b013e328013d9eb _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMarchou, Bruno | |
| 245 | 0 | 0 |
_aIntermittent antiretroviral therapy in patients with controlled HIV infection. _h[electronic resource] |
| 260 |
_bAIDS (London, England) _cFeb 2007 |
||
| 300 |
_a457-66 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntiretroviral Therapy, Highly Active _xadverse effects |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aDrug Resistance, Viral _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aTangre, Philippe | |
| 700 | 1 | _aCharreau, Isabelle | |
| 700 | 1 | _aIzopet, Jacques | |
| 700 | 1 | _aGirard, Pierre-Marie | |
| 700 | 1 | _aMay, Thierry | |
| 700 | 1 | _aRagnaud, Jean-Marie | |
| 700 | 1 | _aAboulker, Jean-Pierre | |
| 700 | 1 | _aMolina, Jean-Michel | |
| 773 | 0 |
_tAIDS (London, England) _gvol. 21 _gno. 4 _gp. 457-66 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/QAD.0b013e328013d9eb _zAvailable from publisher's website |
| 999 |
_c16860931 _d16860931 |
||